Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

GlobeNewswire November 26, 2024

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

GlobeNewswire November 8, 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

GlobeNewswire October 29, 2024

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

GlobeNewswire October 15, 2024

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

GlobeNewswire September 24, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

GlobeNewswire September 4, 2024

Axsome Therapeutics to Participate in Investor Conferences in September

GlobeNewswire August 27, 2024

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

GlobeNewswire August 21, 2024

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 5, 2024

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire July 11, 2024

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

GlobeNewswire June 5, 2024

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

GlobeNewswire June 4, 2024

Axsome Therapeutics Supports Alzheimer's & Brain Awareness Month

GlobeNewswire June 3, 2024

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 30, 2024

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

GlobeNewswire May 29, 2024

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

GlobeNewswire May 28, 2024

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 8, 2024

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 6, 2024

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

GlobeNewswire May 1, 2024